Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy
Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Thanks to rapid reendothelialization derived from the pro-healing property of the EPC capture
stent, 1-month dual antiplatelet therapy (DAPT) is recommended after EPC capture stent
implantation. Shorter maintenance of dual antiplatelet therapy might minimize the risk for
stent thrombosis in cases of discontinuation of antiplatelet regimen and prevent wasteful
medications and bleeding complications related with dual antiplatelet therapy. Thus, the EPC
capture stent might be valuable for the elderly because they are vulnerable to premature
discontinuation of DAPT.
On the other hand, statin upstream therapy has gained popularity because it seems to reduce
periprocedural myocardial injury especially in ACS through its pleiotrophic effect like
plaque stabilization. However, the benefit of pretreatment of statin in patients with stable
angina remains controversial. It is reported that statin administration could increase EPC
level by accelerated differentiation towards the endothelial progenitor lineage.
We hypothesize that the EPC capture stent with 1-month dual antiplatelet therapy is
non-inferior to DES in the elderly subjects with stable coronary artery disease. To test this
hypothesis, we will perform a multi-center, randomized, prospective trial aimed at
demonstrating the efficacy and safety of the EPC capture stent with 1-month DATP versus EES
with standard 12-month DAPT in elderly patients with stable coronary occlusive disease in
real world practice.